For research use only. Not for therapeutic Use.
MGCD-265 analog（Cat No.:I005271）is a multi-targeted kinase inhibitor designed to block key receptors such as MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis, and metastasis. By inhibiting these pathways, MGCD-265 analog disrupts cancer cell proliferation and survival, making it a promising therapeutic candidate for treating various solid tumors, including lung and gastric cancers. Its ability to target multiple receptors simultaneously offers potential for overcoming drug resistance and improving patient outcomes. MGCD-265 analog is being explored in preclinical and clinical studies to assess its efficacy in cancer therapy.
| Catalog Number | I005271 |
| CAS Number | 875337-44-3 |
| Synonyms | N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide |
| Molecular Formula | C26H20FN5O2S2 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| IC50 | 10 nM (VEGFR2), 29 nM(c-Met) |
| IUPAC Name | N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide |
| InChI | InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35) |
| InChIKey | UFICVEHDQUKCEA-UHFFFAOYSA-N |
| SMILES | CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F |
| Reference | </br>1:Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A<sub>4</sub> analog: Protective mechanisms and long-term effects on neurological recovery. Hawkins KE, DeMars KM, Alexander JC, de Leon LG, Pacheco SC, Graves C, Yang C, McCrea AO, Frankowski JC, Garrett TJ, Febo M, Candelario-Jalil E.Brain Behav. 2017 Apr 12;7(5):e00688. doi: 10.1002/brb3.688. eCollection 2017 May. PMID: 28523230 </br>2:The effect of DL-, L-isomers and DL-hydroxy analog administered at 2 levels as dietary sources of methionine on the metabolic and antioxidant parameters and growth performance of turkeys. Jankowski J, Ognik K, Kubinska M, Czech A, Juskiewicz J, Zdunczyk Z.Poult Sci. 2017 May 17. doi: 10.3382/ps/pex099. [Epub ahead of print] PMID: 28521012 </br>3:A New Ergosterol Analog, a New Bis-Anthraquinone and Anti-Obesity Activity of Anthraquinones from the Marine Sponge-Associated Fungus Talaromyces stipitatus KUFA 0207. Noinart J, Buttachon S, Dethoup T, Gales L, Pereira JA, Urbatzka R, Freitas S, Lee M, Silva AMS, Pinto MMM, Vasconcelos V, Kijjoa A.Mar Drugs. 2017 May 16;15(5). pii: E139. doi: 10.3390/md15050139. PMID: 28509846 Free Article</br>4:Response by Wiberg et al to Letter Regarding Article, /Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial/. Wiberg S, Hassager C, Kjaergaard J.Circulation. 2017 May 16;135(20):e1044-e1045. doi: 10.1161/CIRCULATIONAHA.117.027774. No abstract available. PMID: 28507255 </br>5:Letter by Ma et al Regarding Article, /Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial/. Ma LL, Kong FJ, Ge JB.Circulation. 2017 May 16;135(20):e1042-e1043. doi: 10.1161/CIRCULATIONAHA.116.027072. No abstract available. PMID: 28507254 </br>6:A prospective examination of risk factors in the development of intrusions following a trauma analog. Ripley AJ, Clapp JD, Beck JG.Behav Res Ther. 2017 May 5;94:71-80. doi: 10.1016/j.brat.2017.05.001. [Epub ahead of print] PMID: 28505471 </br>7:Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, Shoemaker RH, Warren JD, Elemento O, Kaye KM, Cesarman E.J Clin Invest. 2017 May 15. pii: 83936. doi: 10.1172/JCI83936. [Epub ahead of print] PMID: 28504647 Free Article</br>8:An amylin analog used as a challenge test for Alzheimer/’s disease. Zhu H, Stern RA, Tao Q, Bourlas A, Essis MD, Chivukula M, Rosenzweig J, Steenkamp D, Xia W, Mercier GA, Tripodis Y, Farlow M, Kowall N, Qiu WQ.Alzheimers Dement (N Y). 2017 Jan;3(1):33-43. doi: 10.1016/j.trci.2016.12.002. PMID: 28503657 Free PMC Article</br>9:The Impact of Space Flight on Survival and Interaction of <i>Cupriavidus metallidurans</i> CH34 with Basalt, a Volcanic Moon Analog Rock. Byloos B, Coninx I, Van Hoey O, Cockell C, Nicholson N, Ilyin V, Van Houdt R, Boon N, Leys N.Front Microbiol. 2017 Apr 28;8:671. doi: 10.3389/fmicb.2017.00671. eCollection 2017. PMID: 28503167 Free PMC Article</br>10:Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells. Krause GC, Lima KG, Dias HB, da Silva EFG, Haute GV, Basso BS, Gassen RB, Marczak ES, Nunes RSB, de Oliveira JR.Eur J Pharmacol. 2017 May 10. pii: S0014-2999(17)30334-5. doi: 10.1016/j.ejphar.2017.05.015. [Epub ahead of print] PMID: 28501576 |
